| | DEC - JAN 2021 6EDITOR'S DESKThe stock crash of 2020 has produced a lot of losers. But it's also forged some winners. One of the industries that is most likely to benefit from the COVID-19 outbreak and profit in the long-term is biotech. Sure, they're not always the most stable investments. Firms that risk it all on innovative new tech are a gamble. But biotech, healthcare, and pharma stocks are a solid choice during these uncertain times.For one thing, disease ignores a recession. Even with the economy in hibernation to limit the spread of COVID-19, drug-makers and biotech firms are working hard on new treatments. Biotechnology companies collaborate with stakeholders earlier in the research and development (R&D) cycle and access the best research and development. Networked R&D comprises pharmaceuticals and technology with increased patient engagement to treat and prevent several illnesses. In 2020, R&D will have new horizons that is networked, built around academic and other partnerships. R&D activities are extensively distributed, with firms coordinating and integrating at the center.The emergence of advanced computing technology like machine learning and artificial intelligence allows companies to expand the scope of their research and enhance efficiency in the manufacturing process, which lowers the time it takes for biotech firms to bring products to market. The evolution of cloud computing technology has eliminated a barrier for innovations in biotech. The ability to run applications via the cloud enables firms to store and analyze data without buying expensive computer hardware.The reduced cost of genetic sequencing allows for much more extensive screening of trial participants and targeting of interventions. This has the development of personalized treatment plans and targeted therapies, which are effective than less-specific treatment because they focus on a patient's genetic and molecular makeup. Further, under value-based pricing agreements, buyers and sellers link payments to a specific value achieved as opposed to a volume of sales. These agreements are to align the incentives between the manufacturers and purchasers of an offering--they often require a pricing model different from traditional contracts, and they need clear language to explain terms and conditions. Value-based contracts recognize that both parties are taking a financial risk.Future will be all about Biotechnology Innovation Kenneth Thomas Managing Editoreditor@startupcity.comCopyright © 2021 SiliconMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Dec - Jan - 2021, Volume 4 - Issue 12 (ISSN 2644-2345)Published by SiliconMedia, Inc. To subscribe to Startup CityVisit www.startupcity.com Editorial StaffAaron Pierce Ava Garcia Mia WilliamsDanny RobinsonJoshua ParkerVian IsaacManaging EditorKenneth Thomas*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffSalesRich Gonsalvessales@startupcity.comVisualizersIssac GeorgeEmailsales@startupcity.comeditor@startupcity.commarketing@startupcity.com
< Page 5 | Page 7 >